Atyr Pharma Inc (ATYR)’s latest performance is not what we had anticipated

A new trading day began on Tuesday, with Atyr Pharma Inc (NASDAQ: ATYR) stock price down -5.68% from the previous day of trading, before settling in for the closing price of $3.70. ATYR’s price has ranged from $1.42 to $4.66 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Annual sales at Healthcare sector company grew by 429.49% over the past five years. Meanwhile, its annual earnings per share averaged 17.86%. With a float of $86.00 million, this company’s outstanding shares have now reached $88.86 million.

Let’s look at the performance matrix of the company that is accounted for 59 employees. In terms of profitability, gross margin is -390.64%, operating margin of -28899.57%, and the pretax margin is -27243.4%.

Atyr Pharma Inc (ATYR) Insider Updates

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Atyr Pharma Inc is 3.22%, while institutional ownership is 62.69%. The most recent insider transaction that took place on Mar 17 ’25, was worth 15,000. In this transaction Director of this company bought 3,750 shares at a rate of $4.00, taking the stock ownership to the 9,750 shares. Before that another transaction happened on Feb 04 ’25, when Company’s Chief Financial Officer sold 1,254 for $3.78, making the entire transaction worth $4,740. This insider now owns 31,763 shares in total.

Atyr Pharma Inc (ATYR) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 17.86% per share during the next fiscal year.

Atyr Pharma Inc (NASDAQ: ATYR) Trading Performance Indicators

Here are Atyr Pharma Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1348.35.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.87, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.60 in one year’s time.

Technical Analysis of Atyr Pharma Inc (ATYR)

Atyr Pharma Inc (NASDAQ: ATYR) saw its 5-day average volume 1.12 million, a negative change from its year-to-date volume of 1.31 million. As of the previous 9 days, the stock’s Stochastic %D was 36.05%. Additionally, its Average True Range was 0.34.

During the past 100 days, Atyr Pharma Inc’s (ATYR) raw stochastic average was set at 40.15%, which indicates a significant increase from 39.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 102.69% in the past 14 days, which was higher than the 82.84% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $3.66, while its 200-day Moving Average is $2.72. Nevertheless, the first resistance level for the watch stands at $3.65 in the near term. At $3.81, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.92. If the price goes on to break the first support level at $3.38, it is likely to go to the next support level at $3.27. Assuming the price breaks the second support level, the third support level stands at $3.11.

Atyr Pharma Inc (NASDAQ: ATYR) Key Stats

With a market capitalization of 310.12 million, the company has a total of 88,859K Shares Outstanding. Currently, annual sales are 240 K while annual income is -64,020 K. The company’s previous quarter sales were 0 K while its latest quarter income was -14,970 K.